Some interesting news out of the backyard here in Boulder, Colorado is that Nobel Prize winner Tom Cech, Ph.D. has been appointed as Special Advisor to the Morgenthaler Ventures Life Science Team, assisting Partners in the identification and review of new investment opportunities. Dr. Cech stepped down as President of the Howard Hughes Medical Institute in April 2009 and returned to Colorado to direct the University of Colorado’s Initiative of Molecular Biotechnology.

On the heels of yesterday’s successful “How to Become a VC Magnet” industry panel where Partners from 5AM Ventures and Mohr Davidow Ventures among others were featured, the San Jose Biocenter is queuing up next the Meet With… series con Amgen on 22 April. This is a fantastic platform where early-stage entities are able to identify appropriate individuals to contact within an organization. Then on 3 June an industry panel on Financing Alternatives is scheduled where the expectation is nothing but a candid, interactive and informal exchange of information is to be assured. For more information on these events and more info about the San Jose Biocenter click HERE.

Are you an early-stage entity and thinking about IND-enabling ADME studies? If you are not you certainly should be. Why? Well spend a few moments reading this excellent white paper from the folks at Apredcia, “The Emerging Role of ADME in Venture Capital” and you will see how correlated each step of the therapeutic development path is…

“Pre-clinical ADME Tox (absorption, distribution, metabolism, excretion and toxicology testing) is emerging to take on a role in the drug-discovery venture capital (VC) industry’s financial decisions that corresponds in importance and scope to its established role in the scientific decisions of drug discovery firms. Contract research laboratories that focus on in vitro and in vivo ADME Tox research are seeing increasing involvement of VC firms in all stages of the pre-clinical development process.”

M&A and IPO has been active throughout the quarter. We are currently rolling up all the recent transactions. In addition, the OnBioVC 1Q10 Trend Analysis is only days away. Keep your eyes peeled for its release.

If there is some bioscience-related information of interest that you would like to see covered and aggregated at OnBioVC, please let us know. It is imperative to listen to the demands of the market. OnBioVC strives to be the premiere provider of bioscience investment-related data, and…